The phase III MONALEESA-7 study is investigating the combination of ribociclib with goserelin and tamoxifen or nonsteroidal aromatase inhibitor (NSAI) in premenopausal women with HR+/HER2− advanced breast cancer. This evidence concerns the gene ERBB2 and breast cancer.